{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:04:45Z","timestamp":1773029085149,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS","doi-asserted-by":"publisher","award":["JP 21K15576"],"award-info":[{"award-number":["JP 21K15576"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Microsatellite instability-high is a known biomarker for anti-PD-1\/PD-L1 immune checkpoint therapy. It is also a known tumour feature of Lynch syndrome, detected most frequently in endometrial cancer. However, it remains unclear how microsatellite instability testing is carried out in the clinical field.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Ninety-nine patients with gynaecological malignant tumours who underwent microsatellite instability testing as a companion diagnosis for pembrolizumab and 16 patients who previously underwent microsatellite instability testing as a screening for Lynch syndrome were recruited. Clinical information, microsatellite instability status, outcomes, genetic assessments and information about cancer tissue were retrospectively analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ninety-nine patients had 101 gynaecologic malignant tumours including 26 endometrial, 38 ovarian and 28 cervical cancers, 9 with other tumours including 2 synchronous endometrial and ovarian cancers. All tissue samples were successfully tested, even though some were \u226510-year-old samples. Three cases (3.0%, 3\/99) showed microsatellite instability-high; all cases were endometrial cancers with one case of synchronous endometrial and ovarian cancer [11.5% (3\/26) in endometrial cancer, 2.6% (1\/38) in ovarian cancer], and there was no microsatellite instability-high in cervical and other cancers. One of the endometrial cancer patients received pembrolizumab treatment, but finally died of cancer. Two other cases underwent genetic testing; both were diagnosed as Lynch syndrome. Six cases (37.5%) showed microsatellite instability-high in screening for Lynch syndrome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Microsatellite instability-high was less commonly detected as a companion diagnosis for pembrolizumab in unselected gynaecologic patients. Genetic counselling should be always provided along with treatment selection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyab175","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T19:13:06Z","timestamp":1635189186000},"page":"128-133","source":"Crossref","is-referenced-by-count":1,"title":["Clinical and pathological analysis of companion diagnostic testing of microsatellite instability-high for pembrolizumab in gynaecologic malignancy"],"prefix":"10.1093","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6686-5742","authenticated-orcid":false,"given":"Takashi","family":"Takeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-2845","authenticated-orcid":false,"given":"Yusuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Banno","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9596-8326","authenticated-orcid":false,"given":"Daisuke","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"2022020901371654300_ref1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science (New York, NY)."},{"key":"2022020901371654300_ref2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res."},{"key":"2022020901371654300_ref3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10147-019-01498-8","article-title":"Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition","volume":"25","author":"Mishima","year":"2020","journal-title":"Int J Clin Oncol."},{"key":"2022020901371654300_ref4","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat Med."},{"key":"2022020901371654300_ref5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/cas.14798","article-title":"The real-world data on microsatellite instability status in various unresectable or metastatic solid tumors","volume":"112","author":"Akagi","year":"2021","journal-title":"Cancer Sci."},{"key":"2022020901371654300_ref6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/EDBK_208341","article-title":"Recent advances in Lynch syndrome: diagnosis, treatment, and cancer prevention","volume":"38","author":"Yurgelun","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"2022020901371654300_ref7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.18.00283","article-title":"Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer","volume":"37","author":"Latham","year":"2019","journal-title":"J Clin Oncol."},{"key":"2022020901371654300_ref8","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1002\/cncr.32203","article-title":"Universal endometrial cancer tumor typing: how much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?","volume":"125","author":"Kahn","year":"2019","journal-title":"Cancer."},{"key":"2022020901371654300_ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol."},{"key":"2022020901371654300_ref10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet (London, England)."},{"key":"2022020901371654300_ref11","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1111\/cas.13774","article-title":"Utility of the quasi-monomorphic variation range in unresectable metastatic colorectal cancer patients","volume":"109","author":"Bando","year":"2018","journal-title":"Cancer Sci."},{"key":"2022020901371654300_ref12","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.3802\/jgo.2018.29.e29","article-title":"Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer","volume":"29","author":"Takeda","year":"2018","journal-title":"J Gynecol Oncol."},{"key":"2022020901371654300_ref13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"key":"2022020901371654300_ref14","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-08-1387","article-title":"Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology","volume":"14","author":"Pal","year":"2008","journal-title":"Clin Cancer Res."},{"key":"2022020901371654300_ref15","doi-asserted-by":"crossref","first-page":"112258","DOI":"10.18632\/oncotarget.22733","article-title":"Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer","volume":"8","author":"Hirasawa","year":"2017","journal-title":"Oncotarget."},{"key":"2022020901371654300_ref16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/s12885-018-4489-0","article-title":"Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review","volume":"18","author":"Yokoyama","year":"2018","journal-title":"BMC Cancer."},{"key":"2022020901371654300_ref17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12253-018-0489-2","article-title":"Gene promoter methylation in endometrial carcinogenesis","volume":"25","author":"Cornel","year":"2019","journal-title":"Pathol Oncol Res."},{"key":"2022020901371654300_ref18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ijc.1454","article-title":"Age-related hypermethylation of the hMLH1 promoter in gastric cancers","volume":"94","author":"Nakajima","year":"2001","journal-title":"Int J Cancer."},{"key":"2022020901371654300_ref19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bulcan.2017.06.018","article-title":"Lynch syndrome and endometrial cancer","volume":"104","author":"Bats","year":"2017","journal-title":"Bull Cancer."},{"key":"2022020901371654300_ref20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/his.14026","article-title":"Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tracts","volume":"76","author":"Aird","year":"2020","journal-title":"Histopathology."},{"key":"2022020901371654300_ref21","first-page":"20988","article-title":"Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency","volume":"8","author":"Yuan","year":"2015","journal-title":"Int J Clin Exp Med."},{"key":"2022020901371654300_ref22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.1239947","article-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","volume":"343","author":"Johnson","year":"2014","journal-title":"Science (New York, NY)."},{"key":"2022020901371654300_ref23","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/leu.2014.289","article-title":"Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia","volume":"29","author":"Engle","year":"2015","journal-title":"Leukemia."},{"key":"2022020901371654300_ref24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagn."},{"key":"2022020901371654300_ref25","doi-asserted-by":"crossref","first-page":"300060520931259","DOI":"10.1177\/0300060520931259","article-title":"Effect of preservation time of formalin-fixed paraffin-embedded tissues on extractable DNA and RNA quantity","volume":"48","author":"Yi","year":"2020","journal-title":"J Int Med Res."}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/2\/128\/42404823\/hyab175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/2\/128\/42404823\/hyab175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T02:03:10Z","timestamp":1644372190000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/52\/2\/128\/6423718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,11,9]]},"published-print":{"date-parts":[[2022,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyab175","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2]]},"published":{"date-parts":[[2021,11,9]]}}}